



## **FROST & SULLIVAN RECOGNISES SOMNOMED LIMITED AS OBSTRUCTIVE SLEEP APNEA COMPANY OF THE YEAR AT THE ANNUAL AUSTRALIAN EXCELLENCE AWARDS**

**Sydney, Australia 10<sup>th</sup> December 2015**, SomnoMed Limited (ASX:SOM) was recently recognized and honoured by Frost & Sullivan in their awards for 2015 by receiving Obstructive Sleep Apnea Company of the Year Award.

The award is part of Frost & Sullivan's "Australia Excellence Awards" which are presented each year to companies recognised as the best in their class and have delivered excellence in their respective industries, with the selection process based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.

The annual awards select leading businesses which are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace and have created advanced technologies that will help transform industries in the near future.

SomnoMed Chief Executive Officer Dr Peter Neustadt said, "We are honoured to receive this distinctive recognition from Frost & Sullivan. All of our team in Australia is focused on building a world-class medical device business and providing clinicians and patients with effective, alternative solutions to CPAP to help address the major global medical problem of obstructive sleep apnea. We are all very excited to receive acknowledgement from thought leaders in healthcare for our efforts, especially in Australia where our global head office is based."

SomnoMed is emerging as a significant participant within the treatment of Obstructive Sleep Apnea on a global basis and continues to make significant progress in 2015/2016. The company's investment in technology and product development continues, as well as the expansion into new markets in Europe, contracts with new insurers across two continents and a doubling of the company's manufacturing capacity.

Frost & Sullivan managing director, Australia & New Zealand Mark Dougan said, "Frost & Sullivan believes it is important to highlight industry best practices and acknowledge those who have accomplished noteworthy achievements. Our awards endeavour to identify and spotlight companies that have delivered excellence in their respective industries, as well as spur companies to continue pushing boundaries and share best practices."

**Contact:** Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

### **About SomnoMed**

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 250,000 patients in 26 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>